Comparison of HPV detection technologies: Hybrid capture 2, PreTect™ HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens

Journal of Virological Methods

Volumn 155, Issue 1, 2009, Pages 61-66

  Keegan, Helen ^a   Mc Inerney, Jamie ^a,b   Pilkington, Loretto ^a   Grønn, Petter ^c   Silva, Ivan ^c   Karlsen, Frank ^c   Bolger, Noel ^a   Logan, Catriona ^a,d   Furuberg, Liv ^e   O'Leary, John ^a,b   Martin, Cara ^a,b  

^a Pathology Research Laboratory   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c NorChip AS   (Norway)

^d OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^e SINTEF ICT   (Norway)

Author keywords

E6 E7; HPV viral load; Human papillomavirus; Hybrid capture; mRNA; PreTect HPV Proofer

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ARTICLE; ASSAY; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; FEMALE; HPV PROOFER TEST; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; HYBRID CAPTURE TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

HUMAN PAPILLOMAVIRUS;

EID: 57649128515     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.09.027     Document Type: Article

References (32)

1. Andersson S., Hansson B., Norman I., Gaberi V., Mints M., Hjerpe A., Karlsen F., and Johansson B. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int. J. Oncol. 29 (2006) 705-711
2. Biedermann K., Dandachi N., Trattner M., Vogl G., Doppelmayr H., Moré E., Staudach A., Dietze O., and Hauser-Kronberger C. Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J. Clin. Microbiol. 42 (2004) 3758-3765
3. Castellsagué X., Díaz M., de Sanjosé S., Muñoz N., Herrero R., Franceschi S., Peeling R.W., Ashley R., Smith J.S., Snijders P.J., Meijer C.J., Bosch F.X., and International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98 (2006) 303-315
4. Clifford G., Franceschi S., Diaz M., Muñoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl. 3 (2006) S26-S34
5. Coupé V.M., Berkhof J., Bulkmans N.W., Snijders P.J., and Meijer C.J. Age- dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br. J. Cancer. 98 (2008) 646-651
6. Cuschieri K.S., and Cubie H.A. The role of human papillomavirus testing in cervical screening. J. Clin. Virol. 32 Suppl. 1 (2005) S34-S42
7. Cuschieri K.S., Whitley M.J., and Cubie H.A. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J. Med. Virol. 73 (2004) 65-70
8. Dalstein V., Riethmuller D., Prétet J.L., Le Bail Carval K., Sautière J.L., Carbillet J.P., Kantelip B., Schaal J.P., and Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer. 106 (2003) 396-403
9. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.) 110 (2006) 525-541
10. Evans D.M., Hudson E.A., Brown C.L., Boddington M.M., Hughes H.E., Mackenzie E.F., and Marshall T. Terminology in gynaecological cytopathology: report of the Working Party of the British Society for Clinical Cytology. J. Clin. Pathol. 39 (1986) 933-934
11. Gulliksen A., Solli L.A., Drese K.S., Sörensen O., Karlsen F., Rogne H., Hovig E., and Sirevåg R. Parallel nanoliter detection of cancer markers using polymer microchips. Lab. Chip. 5 (2005) 416-420
12. Gunnell A.S., Ylitalo N., Sandin S., Sparén P., Adami H.O., and Ripatti S. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2641-2648
13. Healey S.M., Aronson K.J., Mao Y., Schlecht N.F., Mery L.S., Ferenczy A., and Franco E.L. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. Sex. Transm. Dis. 28 (2001) 694-700
14. Insinga R.P., Dasbach E.J., Elbasha E.H., Liaw K.L., and Barr E. Progression and regression of incident cervical HPV 6 11 16 and 18 infections in young women. Infect. Agent. Cancer 2 (2007) 15
15. Josefsson A.M., Magnusson P.K., Ylitalo N., Sørensen P., Qwarforth-Tubbin P., Andersen P.K., Melbye M., Adami H.O., and Gyllensten U.B. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2189-2193
16. Keegan H., Ryan F., Malkin A., Griffin M., and Lambkin H. Human papillomavirus prevalence and genotypes in an opportunistically screened Irish female population. Br. J. Biomed. Sci. 61 (2007) 18-22
17. Lo K.W., Yeung S.W., Cheung T.H., Siu N.S., Kahn T., and Wong Y.F. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: a study in Chinese population. J. Clin. Virol. 34 (2005) 76-80
18. Molden T., Kraus I., Skomedal H., Nordstrøm T., and Karlsen F. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods. 142 (2007) 204-212
19. Molden T., Nygård J.F., Kraus I., Karlsen F., Nygård M., Skare G.B., Skomedal H., Thoresen S.O., and Hagmar B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114 (2005) 973-976
20. Moscicki A.B., Schiffman M., Kjaer S., and Villa L.L. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 24 Suppl. 3 (2006) S42-S51
21. Münger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 89 (2002) 213-228
22. Muñoz N. Human papillomavirus and cancer: the epidemiological evidence 2000. J. Clin. Virol. 19 (2000) 1-5
23. Pett M.R., Alazawi W.O., Roberts I., Dowen S., Smith D.I., Stanley M.A., and Coleman N. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 15 (2004) 1359-1368
24. Schiffman M., and Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med. 127 (2003) 946-949
25. Sherman M.E., Wang S.S., Wheeler C.M., Rich L., Gravitt P.E., Tarone R., and Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol. Biomarkers Prev. 10 (2003) 1038-1044
26. Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., and Chu T.Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 76 (2002) 41-47
27. van der Aa M.A., Pukkala E., Coebergh J.W., Anttila A., and Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int. J. Cancer 122 (2008) 1854-1858
28. van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A., van den Brule A.J., Verheijen R.H., Helmerhorst T.J., and Meijer C.J. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int. J. Cancer 98 (2002) 590-595
29. Varnai A.D., Bollmann M., Bankfalvi A., Speich N., Schmitt C., Griefingholt H., Kovács K., Klozoris C., and Bollmann R. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 19 (2008) 457-465
30. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. American Society for Colposcopy and Cervical Pathology-Sponsored Consensus Conference 2006. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am. J. Obstet. Gynecol. 197 (2006) 340-345
31. Wright Jr. T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., Hatch K., Noller K.L., Roach N., Runowicz C., and Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103 (2004) 304-309
32. Ylitalo N., Sørensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Pontén J., Adami H.O., Gyllensten U.B., and Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2194-2198